ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)
Biotechnologia Acta V. 15, No. 5, 2022
P. 24-30. Bibliography. 40, Engl.
UDC 615.014:615.456.3
https://doi.org/10.15407/biotech15.05.024
INFLUENCE OF THE LIPID COMPOSITION ON THE PROPERTIES, TECHNOLOGY AND QUALITY INDICATORS OF LIPOSOMAL DRUGS
D. М. Pylypenko1, G. S. Grigoryeva2, N. F. Konakhovych2, Yu. М. KrasnopolskY.3
1State Biotechnological University, Ukraine, Kharkiv
2State Institution “Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine”, Kharkiv
3National Technical University “Kharkiv Polytechnic Institute”, Ukraine
Liposomal drug delivery system is an example of the use of nanodrugs in medical practice. Encapsulation of active pharmaceutical ingredients in liposomal nanoparticles allows increasing their bioavailability and efficacy.
Aim. The article is devoted to the analysis of the lipid composition of liposomal drugs developed in Ukraine, its influence on the choice of technology and control parameters.
Results. The lipid compositions of liposomal drugs developed in Ukraine in recent years were reviewed. The advantages and disadvantages of natural phosphatidylcholine as the main membrane-forming lipid were analyzed. Data on the influence of anionic phospholipids and cholesterol in the liposomal membrane composition on the stability of liposomal nanoparticles and the level of active pharmaceutical ingredient encapsulation were given. The main technological stages of obtaining liposomes with hydrophilic and hydrophobic active pharmaceutical ingredients were considered. The main groups of quality indicators of liposomal dosage forms have been determined.
Conclusions. The lipid composition determines the structure and physicochemical properties of the lipid membrane, the mechanism and level of active pharmaceutical ingredient encapsulation, which significantly influences the pharmacological efficacy of liposomal drug delivery systems.
Key words: nanobiotechnology; drug delivery system; liposomal drug; phospholipids; anionic phospholipids; phosphatidylcholine; cholesterol.
© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2022
References
1. Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res. Lett. 2021, 16(1), 95. https://doi.org/10.1186/s11671-021-03553-8
2. Shvets V.I., Krasnopolskiy Yu.M., Sorokoumova G.M. Liposomal forms of drugs: technological features of production and use in the clinic. M.: Remedium, 2016. 200 p. (In Russian).
3. Bulbake U., Doppalapudi S., Kommineni N., Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017, 9(2), 12. https://doi.org/10.3390/pharmaceutics9020012
4. Allen T. M., Cullis P. R. Liposomal drug delivery systems: from concept to clinical application. Adv. Drug. Deliv. Rev. 2013, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
5. Khromov A. S. Liposomal drugs – implementation of nanotechnology in medicine. Pharmacol. Drug Toxicol. 2016, 2(48), 14–23. (In Russian).
6. Dudnitchenko A. S., Krasnopolsky Yu. M. Preparation and pharmacokinetics in vivo of liposome-associated anthracyclines and 5-fluorouracil. Exp. Oncol. 1996, 18(4), 392–396.
7. Krasnopolskii Y. M., Grigor’eva A. S., Katsai A. G., Konakhovich N. F., Prokhorov V. V., Stadnichenko A. V. Balaban’yan V. Yu., Lyutik A. I., Shvets V. I. Technologies and perspectives of liposomal drug application in clinical practice. Nanotechnol. Russ. 2017, 12 (7-8), 461–470. http://doi.org/10.1134/s1995078017040139
8. Anchordoquy, T. J., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Dobrovolskaia, M. A., Farhangrazi, Z. S., Farrell, D., Gabizon, A., Ghandehari, H., Godin, B., La-Beck, N. M., Ljubimova, J., Moghimi, S. M., Pagliaro, L., Park, J. H., Peer, D., Ruoslahti, E., Serkova, N. J., Simberg, D. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano. 2017, 11(1), 12–18. https://doi.org/10.1021/acsnano.6b08244
9. Pivnuk V.M., Tymovska Yu.O., Ponomareva O.V., Kulyk G.I., Olyinichenko G.P., Anikusko M.F., Krasnopolsky Yu.M., Chekhun V.F. Applying of liposomal form of doxorubicin in patients with doxorubicin-resistant breast cancer. Oncol. 2007, 9(2), 120–124. (In Ukrainian).
10. Magar K. T., Boafo G. F., Li X., Chen Z., He W. Liposome-based delivery of biological drugs. Chinese Chem. Lett. 2022, 33(2), 587–596. https://doi.org/10.1016/j.cclet.2021.08.020
11. Krasnopolsky Yu. М., Pylypenko D. М. “Quality By Design” in liposomal drugs creation. Biotechnologia ACTA. 2020, 13(6), 5–12. https://doi.org/10.15407/biotech13.06.005
12. Shvets V. I., Sennіkov G. A., Golbec I. I. Krasnopolsky Y. M. Production of purified lecithin. Farmac. J. 1977, 4, 79–81. (In Ukrainian).
13. Webb M. S., Bally M. B., Mayer L. D., Miller J. J., Tardi P. G. Sphingosomes for enhanced drug delivery. US Patent. 5741516. April 21, 1998.
14. Hryhorieva H. S., Katsai O. H., K.rasnopolskyi Yu. M., Prokhorov V. V., Khromov O. S., Pasiechnikova N. V., Dobrelia N. V. The method of obtaining a pharmacologically active liposomal composition containing cytochrome C, and a liposomal composition obtained by this method. Ukrainian patent № 118583. February 11, 2019.
15. Pylypenko D. M., Krasnopolsky Yu. M. A method of preparing a complex liposomal composition containing quercetin and curcumin. Ukrainian patent № 147767. June 09, 2021.
16. Pylypenko D. M., Gorbach T. V., Katsai O. G., Grigoryeva A. S., Krasnopolsky Y. M. A Study of Oxidative Stress Markers when Using the Liposomal Antioxidant Complex. Pharmakeftiki. 2019, 31(1), 40–47.
17. Pylypenko D., Gorbach T. Krasnopolsky Yu. Study of antioxidant activity of liposomal forms of quercetin and curcumin ischemic heart disease. BioTechnologia. 2020, 101(4), 273–282. https://doi.org/10.5114/bta.2020.100420
18. Feng T., Wei Y., Lee R. J., Zhao L. Liposomal curcumin and its application in cancer. Int. J. Nanomedicine. 2017, 12, 6027–6044. https://doi.org/10.2147/IJN.S132434
19. Vetha B. S. S., Kim E. M., Oh P. S., Kim S. H, Lim S. T., Sohn M. H., Jeong H. J. Curcumin encapsulated micellar nanoplatform for blue light emitting diode induced apoptosis as a new class of cancer therapy. Macromol. Res. 2019. 27, 1179–1184. https://doi.org/10.1007/s13233-019-7168-3
20. Subramani P. A., Panati K., Narala V. R. Curcumin nanotechnologies and its anticancer activity. Nutr Cancer. 2017, 69(3), 381–393. https://doi.org/10.1080/01635581.2017.1285405
21. Krasnopolsky Y. M., Dudnichenko А. S. Experimental study of liposomal docetaxel incorporation and stability. Exp. Oncol. 2017, 39(2), 121–123. https://doi.org/10.31768/2312-8852.2017.39(2):121-123
22. Shobolov D.L., Krasnopol'skij Ju.M., Ul'janov A.M. Natykan A. A., Tarasov V. V., Balaban'jan V. Ju., Shvec V. I., Prohorov V. V. Method for producing liposomal form of docetaxel. Eurasian patent № 022182. November 30, 2015.
23. Dudnychenko O. S., Temirov Yu. P., Butenko K. A., Krasnopolskyi Yu. M. The method of obtaining the liposomal form of an anticancer drug. Ukrainian patent № 14629. January 20, 1997.
24. Dudnychenko A. S., Temirov Yu. P., Shvets V. I., Krasnopolskyi Yu. M., Sennikova I. H. A method of obtaining a liposomal form of an antitumor antibiotic. Ukrainian patent № 64591. January 16, 2006.
25. Pobedimsky D. D., Stepanov A. E., Kaplun A. P., Krasnopolsky Yu. M., Dudnichenko A. S., Pobedimsky D. G., Shvets V. I. Development of technology for the production of Lipodox – a liposomal form of doxorubicin. Chemistry and Market. 2004, 3, 13–22.
26. Shobolov D. L., Krasnopol'skij Ju. M., Ul'janov A. M. Natykan A. A., Tarasov V. V., Balaban'jan V. Ju., Shvec V. I. Method of obtaining liposomal form of irinotecan. Eurasian patent № 023079. April 29, 2016.
27. Stadnichenko A. V., Dudnichenko A. S., Krasnopolskiy Yu. M. Liposomal anticancer drugs. Kharkov : «Madrid», 2018. 256 p. (In Russian).
28. Hryhorieva G. S., Krasnopolsky Yu. M., Konakhovich N. F., Pasechnikova N. V. The method of obtaining a pharmacologically active liposomal agent containing quercetin. Ukrainian patent № 111762. June 18, 2016.
29. Hryhorieva A. S., Konakhovych N. F., Stefanov O. V., Krasnopolskyi Yu. M., Temirov Yu. P., Riabushev M. B. А method of obtaining a liposomal hepatoprotective agent. Ukrainian patent № 46528. December 15, 2003.
30. Ryabushev M.B., Grigor'eva G.S., Konakhovich N.F. Membranoprotective action of liposomal hepatoprotector "Lioliv". Medicine. 2001, 5-6, 74–79. (In Ukrainian).
31. Vafadar A., Shabaninejad Z., Movahedpour A., Fallahi F., Taghavipour M., Ghasemi Y., Akbari M., Shafiee A., Hajighadimi S., Moradizarmehri S., Razi E., Savardashtaki A., Mirzaei H. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci. 2020, 10, 32. https://doi.org/10.1186/s13578-020-00397-0
32. Hashemzaei M., Delarami Far A., Yari A., Heravi R. E., Tabrizian K., Taghdisi S. M., Sadegh S. E., Tsarouhas K., Kouretas D., Tzanakakis G., Nikitovic D., Anisimov N. Y., Spandidos D. A., Tsatsakis A. M., Rezaee R. Anticancer and apoptosis‑inducing effects of quercetin in vitro and in vivo. Oncol. Rep. 2017, 38(2), 819–828. https://doi.org/10.3892/or.2017.5766
33. Liu Y., Gong W., Yang Z. Y., Zhou X. S., Gong C., Zhang T. R., Wei X., Ma D., Ye F., Gao Q. L. Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer. Apoptosis. 2017, 22(4), 544–557. https://doi.org/10.1007/s10495-016-1334-2
34. Stefanov A. V., Bryginsky S. A., Lishko V. K., Krasnopolsky Yu. M. Method for obtaining an antihypoxic agent in liposomal form. Author's certificate of the USSR No. 1699343 A3. December 15, 1991.
35.Grigorieva G. S., Krasnopolsky Yu. M. Liposomes per se pharmacotherapeutic status. Pharmacol. Drug Toxicol. 2020, 14(4), 264–271. https://doi.org/10.33250/14.04.264
36. Pylypenko O. Ya., Grigoryeva G. S., Krasnopolskyi Yu. M., Konakhovich N. F., Myheitseva I. M., Pasyechnikova N. V., Prokhorov V. V. The method of obtaining a liposomal composition containing latanoprost, and a pharmacologically active liposomal composition for ophthalmology obtained by this method. Ukrainian patent № 124724. November 02, 21.
37. Krasnopolsky Yu. M., Stepanov A. E., Shvets V. I. Analysis of Risk Factors Under Production of Preparation Based on Biotechnology. Third Russian Symposium with International Participation BIOPHARMA-2011: from science to industry. Tel Aviv, 2011. P. 12–13.
38. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Guidance for industry. FDA, Center for Drug Evaluation and Research (CDER), 2018, 15 p.
39. Borschevsky G.I., Tovmasyan E.K., Krasnopolsky Yu.M., Gryzodub O.I. Standardization of liposome drug products. Farmakom. 2013, 2, 5–11. (In Russian)
40. State Pharmacopoeia of Ukraine 2.0. Vol. 1. 2015, 1036–1038. (In Ukrainian)